Connecticut is considering SB 270, a bill that seeks to limit physician-pharmaceutical industry interaction.
Connecticut joins New York, Minnesota, and many other states by considering SB 270, a bill that seeks to limit physician-pharmaceutical industry interaction. During a debate in late February in a Public Health Committee hearing for the Connecticut General Assembly, the bill’s sponsor, Connecticut Attorney General Richard Blumenthal, said that although “certain pharmaceutical drug companies are taking steps toward self-reform,” there’s still a need for “a state law readily enforceable by ...
Register for Complete Access (Valid Email Required)
By registering on MeetingsNet now, you'll not only unlock the Connecticut Considers Pharma Bill SB 270, you'll also gain access to exclusive premium content.